Invest in

Drug-Patent Cliffs

2.4%
3.8%
0.4%

Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See More
2.4%
3.8%
0.4%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for as low as $9.95.
Join over 100,000 Motif customers customizing, building, and sharing motifs.
Portfolio Index 1 YR Return
Drug-Patent Cliffs Benchmark
Open a Motif account to view and trade this thematic portfolio
Weight Segment & Stocks Symbol 1 YR Return
51.1% Biosimilar 10.9%
10.7% Pfizer Inc. PFE 13.9%
10.3% Sanofi SNY 7.6%
10.2% Allergan plc AGN 11.0%
10.0% 8xx 8xxxx 8xx 8xxxxxx 8xx 88.8%
9.8% 8xxxxxxx 8x 8xx 88.8%
48.9% Generic Drugs 7.8%
9.6% 8xxxxxxxxxx 8xx 8xx 8xx 88.8%
8.0% 8xxxxxxx 8xxxxxxxxxx 8xx 88.8%
7.7% 8xx 8xxxxxx 8xxxxxxxxxxx 8xx 8xx 88.8%
4.4% 8xxxx 8xxx 8xx 88.8%
4.0% 8xxx 8xxxxxxxxxxxxx 8xxxxxxxxx 8xxxxxx 8 8xxx 88.8%
2.3% 8xxxxx 8xxxxx 8xxxxxxxx 8xxx 8xx 88.8%
2.2% 8xxx 8xxxxxxxxxxxxx 8xxxxxxxxx 8xxx 8xxx 88.8%
1.8% 8xxxx 8xxx 8xxx 88.8%
1.7% 8xxxxxx 8xxxxxxxxxx 8xx 88.8%
1.6% 8xxxxxx 8xxxxxx 8xx 8xxx 88.8%
1.4% 8xxxxxxxx 8xxxxxxxxxxxxxx 8xxx 8xxx 88.8%
1.1% 8xxxxx 8xxxxxxxxxxxxxx 8xxx 8xxxx 8 8xxx 88.8%
1.1% 8xxx 8xxxxxxxxxxxx 8xx 8xxx 88.8%
1.1% 8xxxxxxxxxxx 8xx 8xx 88.8%
1.0% 8xxxxxx 8x 8xx 8xx 88.8%
Quotes delayed 15 mins. Currently May 19, 2019 10:45:48 PM. Fields are marked with -- when data is unavailable.